• Home
  • Cardiovascular diseases Publications

Cardiovascular diseases Publications

Cardiovascular diseases Publications

  • Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.Abstract

    BACKGROUND: Trials of weight-loss drugs indicate some benefits on lipids, blood glucose, or blood pressure levels. Since obesity is associated with increased cardiovascular (CV) medication use and pharmaceutical costs, weight-loss drug use could beeficially impact CV medication use. OBJECTIVE: We examined the temporal associations between CV drugs use 3 years before and after the initiation of orlistat, a weight-loss drug

    Czernichow S, Knol MJ, Fezeu L, Grobbee DE. Eur J Prev Cardiol. 2012 Jun; 19 (3): 484-9.
  • The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease.Abstract

    The aim of present study was to investigate the risk of heart failure associated with dopamine agonist use in patients with Parkinson’s disease. The data sources of this study were four different population-based, healthcare databases in United Kindom, Italy and Netherlands. A case control study nested within a cohort of Parkinson’s disease patients who were new users of either dopamine agonist or levodopa was conducted

    Mokhles MM, Trifiro G, Dieleman JP, Haag MD, van Soest EM, Verhamme KM, Mazzaglia G, Herings R, de Luise C, Ross D, Brusselle G, Colao A, Haverkamp W, Schade R, van Camp G, Zanettini R, Sturkenboom MC. Pharmacol Res. 2012 Mar; 65 (3): 358-64.
  • Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case-control study.Abstract

    BACKGROUND: It has been suggested that ergoline dopamine agonists can cause ischemic complications. The effect of dopamine agonists in general on the prevalence of ischemic events in patients with Parkinson’s disease (PD) has not been studied. OBJETIVE: Our aim was to investigate the association between the use of dopamine agonists and hospitalization due to ischemic events in patients with PD

    Arbouw ME, Movig KL, Guchelaar HJ, Neef C, Egberts TC. Eur J Clin Pharmacol. 2012 Jan; 68 (1): 83-8.
  • Cardiovascular comorbidities among patients with metastatic colorectal cancer.Abstract

    Aim: As comorbidities may impact treatment decisions, prognoses and quality of care, this study determined the rate of comorbid cardiovascular diseases in patients with metastatic colorectal cancer (mCRC). Methods: From the PHARMO Record Linkage Sytem in The Netherlands, all patients with a hospital discharge code for CRC and distant metastasis from 2000-2008 were selected

    Overbeek JA, Zhao Z, van Herk-Sukel MP, Barber BL, Herings R. Journal of Cancer Therapeutics & Research. 2012 online.
  • Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.Abstract

    PURPOSE: To determine the thromboprophylactic treatment pattern and occurrence of venous thromboembolism (VTE), major bleeding, and wound infections in patients undergoing total knee replacement (TKR) or total hip replacement (THR). METHODS: From te PHARMO database, all patients >/= 18 years hospitalized for TKR or THR between January 2003 and September 2008 were selected

    Penning-van Beest FJ, Overbeek JA, Meijer WM, Woodruff K, Jackson J, van der Vis H, van der Linden P, Herings RM. Pharmacoepidemiol Drug Saf. 2011 Sep; 20 (9): 972-8.
  • Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI.Abstract

    Genetic variability has been shown to affect statin responsiveness. Participants from the Utrecht Cardiovascular Pharmacogenetics (UCP) studies were enrolled from a population-based registry of pharmacy records linked to hospital discharge recordsPHARMO) to investigate tagging SNPs within candidate genes involved in the cholesterol lowering pathway for modification of the effectiveness of statins in reducing the risk of myocardial infarction (MI)

    Peters BJ, Pett H, Klungel OH, Stricker BH, Psaty BM, Glazer NL, Wiggins KL, Bis JC, deBoer A, Maitland-van der Zee AH. Atherosclerosis. 2011 Aug; 217 (2): 458-64.
  • Myocardial infarction, ischaemic stroke and pulmonary embolism before and after breast cancer hospitalisation. A population-based study.Abstract

    We studied the occurrence of myocardial infarction (MI), ischaemic stroke (IS) and pulmonary embolism (PE) before and after breast cancer hospitalisation compared with cancer-free controls. For this, women with a first breast cancer hospitalisationduring 2000-2007 were selected from the PHARMO Record Linkage System, including drug use and hospitalisations of three million inhabitants in the Netherlands, and matched 1:10 by age to cancer-free women

    van Herk-Sukel MP, Shantakumar S, Kamphuisen PW, Penning-van Beest FJ, Herings RM. Thromb Haemost. 2011 Jul; 106 (1): 149-55.
  • Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism.Abstract

    PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with an increased risk of arterial thrombosis, but their effect on venous thrombotic events is less well established. The study aimed to assess the risk of symptomatic pulonary embolism (PE) in patients using NSAIDs and to evaluate any effect of type, dose, and duration of therapy

    Biere-Rafi S, DiNisio M, Gerde s V, Porreca E, Souverein P, Boer A, Buller H, Kamphuisen P. Pharmacoepidemiol Drug Saf. 2011 Jun; 20 (6): 635-42.
  • Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study.Abstract

    AIMS: We assessed, in patients with a first hospitalization for heart failure (HF), the temporal relationship of the incidence of cardiovascular events, all-cause mortality, and cardiovascular drug treatment. METHODS AND RESULTS: Data were obtainedfrom the PHARMO Record Linkage System, a population-based registry of pharmacy records linked with hospital discharge records in The Netherlands

    de Peuter OR, Lip GY, Souverein PC, Klungel OH, de Boer A, Buller HR, Kamphuisen PW. Eur J Heart Fail. 2011 May; 13 (5): 489-95.
  • Estimates of statin discontinuation rates are influenced by exposure and outcome definitions.Abstract

    BACKGROUND: Estimates of statin discontinuation rates are generally high but show large variations. Discontinuation rates are possibly influenced by unrecognized supplies from previous prescriptions and the operational definitions of statin discontnuation. OBJECTIVE: To investigate whether the outcome (discontinuation) was affected by (1) the operational definition used to calculate statin exposure and (2) the operational definition and different cutoff values used to calculate discontinuation

    Geers HC, Bouvy ML, Heerdink ER. Ann Pharmacother. 2011 May; 45 (5): 576-81.